JMJohn C. Marshall

John C. Marshall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John C. Marshall has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • THE EFFECTS OF GRANULOCYTE COLONY-STIMULATING FACTOR IN PRECLINICAL MODELS OF INFECTION AND ACUTE INFLAMMATION

    by John C Marshall

    The cytokine granulocyte colony-stimulating factor (G-CSF) is a potent endogenous trigger for the release of neutrophils from bone marrow stores and for their activation for enhanced antimicrobial activity. G-CSF has been widely evaluated in preclinical models of acute illness, with generally promising though divergent results. A recombinant G-CSF molecule has recently undergone clinical trials to assess its efficacy as an adjuvant therapy in community-acquired and nosocomial pneumonia, however, these studies failed to provide convincing evidence of benefit. We undertook a systematic review of the published literature reporting the effects of modulation of G-CSF in preclinical in vivo models to determine whether evidence of differential efficacy might explain the disappointing results of human studies and point to disease states that might be more likely to benefit from G-CSF therapy. G-CSF has been evaluated in 86 such studies involving a variety of different models. The strongest evidence of benefit was seen in studies involving intraperitoneal challenge with live organisms; benefit was evident whether the agent was given before or after challenge. G-CSF demonstrates anti-inflammatory activity in models of systemic challenge with viable organisms or endotoxin, but only when the agent is given before challenge; evidence of benefit after challenge was minimal. Preclinical models of intrapulmonary challenge only show efficacy when the cytokine is administered before the infectious challenge, and suggested harm in gram-negative pneumonia resulting from challenge with Escherichia coli or Klebsiella. There is little evidence for therapeutic efficacy in noninfectious models of acute illness. We conclude that the most promising populations for evaluation of G-CSF are neutropenic patients with invasive infection and patients with intra-abdominal infection, particularly those with the syndrome of tertiary, or recurrent, peritonitis. Significant variability in the design and reporting of studies of preclinical models of acute illness precludes more sophisticated data synthesis.


  • Intra-abdominal infections

    by John C. Marshall


  • Open Access

    Diagnostic and Prognostic Implications of Endotoxemia in Critical Illness: Results of the MEDIC Study

    by John C. Marshall, Debra Foster, Jean‐Louis Vincent, Deborah J. Cook, Jonathan Cohen, R. Phillip Dellinger, Steven Opal, Edward Abraham, Stephen J. Brett, Terry Smith, et al.

    A novel assay for endotoxin, based on the ability of antigen-antibody complexes to prime neutrophils for an augmented respiratory burst response, was


  • Sepsis: current status, future prospects

    by John C Marshall

    The diseases of critical illness are rooted in the response of the host to clinical interventions that have thwarted imminent death. Sepsis—the clinical syndrome that embodies the systemic host response to microbial invasion—exemplifies the dynamic interplay between an external threat and the endogenous response of the host that has created the phenotype of critical illness. Critical illness is a pathophysiologic state without evolutionary precedent. It is only in the past century that shock was transformed from a lethal disease to a physiologic state that was reversible by the administration of intravenous fluids [1], or that acute respiratory insufficiency caused by polio or renal failure resulting from trauma were readily supported by positive pressure ventilation and dialysis respectively. These successes came at a cost that is still incompletely understood, as survival from shock gave rise to the acute pulmonary insufficiency of the acute respiratory distress syndrome (ARDS) [2,3], and the interventions used to manage ARDS, in turn, triggered further injury in remote organs [4], and contributed to the evolution of the multiple organ dysfunction syndrome (MODS) [5]. The word “sepsis” comes from the Greek ση´ψις, meaning rot or putrefaction, and is attributed to Hippocrates [6]. In the Hippocratic model, living tissues broke down by one of two contrasting processes. Pepsis was the process through which foodstuffs were digested, fostering growth and well being, or that grapes were fermented to produce wine. Sepsis, on the other hand, denoted tissue breakdown that resulted in a foul order and illness, and that was exemplified by swamps and festering wounds. The work of Semmelweis, Pasteur, and Lister in the nineteenth century established definitively that the processes of infection and suppuration were caused by microscopic living organisms, and so the word “sepsis” became synonymous with overwhelming invasive infection; indeed, a medical dictionary from 1972 defines sepsis as “... the presence of pus-forming organisms in the bloodstream ...” [7]. But anti-infective therapies have had only a modest impact on the morbidity and mortality of sepsis. Data from the Center for Disease Control in the United States show a dramatic reduction in the toll of infectious diseases over the twentieth century, with mortality rates falling from approximately 800 in 100,000 at the turn of the century to 70 in 100,000 at its close [8] (Fig. 1). A closer review of these successes shows that the largest decrease in mortality occurred before the widespread availability of antibiotic agents, and well before the establishment of the first ICU in 1957 [9]. Rather the mortality reduction reflects the introduction of such public health measures as immunizations, the establishment of public health departments, and the pasteurization of milk, and mortality rates in the second half of the twentieth century have been relatively unchanged. The conclusions of this population-based analysis are mirrored in a study of infections in a single hospital in the decades immediately before (the 1930s) and after (the 1950s) the introduction of antimicrobial therapy into clinical practice. Neither the rates nor the mortality of infection was changed; instead, the most striking impact of antibiotics was on the microbiology of infection in the hospitalized patient, with a shift from exogenous to endogenous organisms as the predominant infecting species [10]. As the pathophysiologic mechanisms of sepsis are becoming better understood, it has become apparent that the clinical syndrome arises not from the direct effects of the microbial trigger, but indirectly, through the systemic activation of an innate immune response.


  • Open Access

    Pre–B cell colony–enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis

    by Song Hui Jia, Yue Li, Jean Parodo, Andras Kapus, Lingzhi Fan, Ori D. Rotstein, John C. Marshall

    Pre–B cell colony-enhancing factor (PBEF) is a highly conserved 52-kDa protein, originally identified as a growth factor for early stage B cells. We show here that PBEF is also upregulated in neutrophils by IL-1β and functions as a novel inhibitor of apoptosis in response to a variety of inflammatory stimuli. Induction of PBEF occurs 5–10 hours after LPS exposure. Prevention of PBEF translation with an antisense oligonucleotide completely abrogates the inhibitory effects of LPS, IL-1, GM-CSF, IL-8, and TNF-α on neutrophil apoptosis. Immunoreactive PBEF is detectable in culture supernatants from LPS-stimulated neutrophils, and a recombinant PBEF fusion protein inhibits neutrophil apoptosis. PBEF is also expressed in neutrophils from critically ill patients with sepsis in whom rates of apoptosis are profoundly delayed. Expression occurs at higher levels than those seen in experimental inflammation, and a PBEF antisense oligonucleotide significantly restores the normal kinetics of apoptosis in septic polymorphonuclear neutrophils. Inhibition of apoptosis by PBEF is associated with reduced activity of caspases-8 and -3, but not caspase-9. These data identify PBEF as a novel inflammatory cytokine that plays a requisite role in the delayed neutrophil apoptosis of clinical and experimental sepsis.


  • Open Access

    Transfusion trigger: when to transfuse?

    by John C Marshall

    The decision to transfuse a hospitalized patient must balance the known risks of transfusion with the need to provide adequate tissue oxygenation and the appropriate utilization of blood as a scarce resource. The minimum tolerated hemoglobin level is not well established, and considerable variation exists in intensivists' transfusion practices. Conventional transfusion triggers of 100 g/l have been challenged by reports indicating that aerobic metabolism is supported by hemoglobin levels of 50 g/l or less. Evidence from randomized trials also indicates that withholding transfusions may result in improved outcomes. Arbitrary numeric hemoglobin triggers, however, cannot supercede intervention based on individual physiologic need and clinical circumstances.


  • Intensive care unit management of intra-abdominal infection

    by John C. Marshall, Marilyn Innes

    To review the biologic characteristics of, and management approaches to, intra-abdominal infection in the critically ill patient. Narrative review. Medline review focussed on intra-abdominal infection in the critically ill patient. Restricted to studies involving human subjects. None. Intra-abdominal infections are an important cause of morbidity and mortality in the intensive care unit (ICU). Peritonitis can be classified as primary, secondary, or tertiary, the unique pathologic features reflecting the complex nature of the endogenous gut flora and the gut-associated immune system, and the alterations of these that occur in critical illness. Outcome is dependent on timely and accurate diagnosis, vigorous resuscitation and antibiotic support, and decisive implementation of optimal source control measures, specifically the drainage of abscesses and collections of infected fluid, the debridement of necrotic infected tissue, and the use of definitive measures to prevent further contamination and to restore anatomy and function. Optimal management of intra-abdominal infection in the critically ill patient is based on the synthesis of evidence, an understanding of biologic principles, and clinical experience. An algorithm outlining a clinical approach to the ICU patient with complex intra-abdominal infection is presented.


  • Measures, markers, and mediators: Toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25–26, 2000

    by John C. Marshall, Jean-Louis Vincent, Mitchell P. Fink, Deborah J. Cook, Gordon Rubenfeld, Debra Foster, Charles J. Fisher, Eugen Faist, Konrad Reinhart

    Sepsis is not a single disease but a complex and heterogeneous process. Its expression is variable, and its severity is influenced by the nature of the infection, the genetic background of the patient, the time to clinical intervention, the supportive care provided by the clinician, and a number of factors as yet unknown. The evaluation of effective therapies has been hampered by limitations in our ability to characterize the process and to stratify patients into more homogeneous groups with respect to pathogenesis. To develop a taxonomy of markers relevant to clinical research in sepsis and to propose a testable candidate system for stratifying patients into more therapeutically homogeneous groups. An expert roundtable discussion and a MEDLINE review using search terms “marker” and “sepsis.” Markers provide information in one or more of three domains: diagnosis, prognosis, and response to therapy. More than 80 putative markers of sepsis have been described. All correlate with the risk of mortality (prognosis), yet none has shown utility in stratifying patients with respect to therapy (diagnosis) or in titrating that therapy (response). Their limitations arise from the challenges of establishing causality in a complex disease process such as sepsis and of stratifying patients into more homogeneous populations. The former limitation may be addressed through a modification of Koch’s postulates to differentiate causality from simple association. The latter suggests the need for a staging system analogous to those used in other complex disease processes such as cancer. A candidate framework for such a system, based on the infection, the host response, and the extent of organ dysfunction (the IRO system) is described. Advances in the understanding and management of patients with sepsis will necessitate more rigorous approaches to disease description and stratification. Models should be developed, tested, and modified through clinical studies rather than through consensus.